



CURRICULUM VITAE

Koichi Takahashi, M.D., Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

CITIZENSHIP

Japan, O Visa

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Unit 428
Unit Number: Unit 428
Houston, TX 77030
Room Number: FC4.3058
Phone: 713-745-4613
Fax: 713-792-4297
Email: ktakahashi@mdanderson.org

EDUCATION

Degree-Granting Education

Niigata University Faculty of Medicine, Niigata, Japan, MD, 2006, Medicine

Kyoto University, Kyoto, Japan, PHD, 2020, Medicine

Postgraduate Training

Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo, Japan, Yasuhiro Takeuchi M.D., Ph.D., 4/2006-6/2008

Clinical Residency, Internal Medicine, Beth Israel Medical Center, New York, NY, Daniel Steinberg M.D., 7/2008-6/2011

Clinical Fellowship, Hematology/Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Robert Wolff M.D., 7/2011-6/2014

CREDENTIALS

Board Certification

American Board of Internal Medicine, 323588, 10/2011-12/2021

American Board of Hematology, 12/2014-12/2024

American Board of Medical Oncology, 12/2014-12/2024

Licensures

Active

Japanese National Medical License, Japan, 460189, 3/2006

Texas Medical Board, TX, Q2073, 11/2014-11/2021

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2014-present

Assistant Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2015-present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

Co-founder and Chair, Beth Israel Research Society, New York, NY, 9/2010-6/2011

Endowed Positions

N/A

Consultantships

Symbio Pharma, Tokyo, Japan, Scientific Advisory Board, 7/2017-present

Military or Other Governmental Service

N/A

Institutional Committee Activities

Data and Biospecimen Access Committee, Member, 3/2017-present

Decisive Discoveries Focus Working Group "Key Knowledge Gaps in Biology", Member, 9/2017-present

HONORS AND AWARDS

Celgene Future Leaders in Hematology Award, Celgene, 2012

The Janice Davis Singletary Fellowship of Lymphoma Research, 2012

Abstract Achievement Award, American Society of Hematology, 2013

The Kimberly Patterson Leukemia Research Fellowship, 2013

Achievement in Basic Research Award, The University of Texas MD Anderson Cancer Center, 2014

Merit Award, American Society of Clinical Oncology, 2014

Research Training Award for Fellows, American Society of Hematology, 2014

Travel Award, European Haematology Association, 2014, 2016

Khalifa Scholar Physician Scientist Award, The University of Texas MD Anderson Cancer Center, 2016

Andrew Sabin Family Fellow, 2020

Junior Faculty Scholar Award in Basic Translational Research, American Society of hematology, 2020

RESEARCH

Grants and Contracts

Funded

Principal Investigator, 20%, Physician Scientist Program Award, MD Anderson Cancer Center, 9/1/2017-6/30/2021, \$500,000 (\$125,000/year)

Principal Investigator, 1.2 months, Start Up Funds for Tenure-Track Faculty, MD Anderson Cancer Center, 9/1/2017-8/31/2022, \$750,000 (\$150,000/year)

Co-Investigator, 1.2 months, PPM1D in clonal hematopoiesis and malignancies, 5R01CA237291, Baylor College of Medicine, PI - Goodell M, 7/1/2019-6/30/2024, \$420,024 (\$88,298/year)

Co-Investigator, 1%, Elucidating Evolutionary History of Clonal Hematopoiesis, UTMDACC MDS/AML Moon Shot - Project 4, 9/1/2020-8/31/2021, \$223,425 (\$223,425/year)

Principal Investigator, 5%, UTMDACC Leukemia SPORE Development Award:: Mapping the genetic and phenotypic heterogeneity in AML and its clinical significance., P50 CA100632-18, NIH/NCI, 9/1/2020-8/31/2021, \$50,000 (\$50,000/year)

Principal Investigator, 10%, Clonal Diversity in Acute Myeloid Leukemia (AML) and Its Clinical Implications, The Andrew Sabin Family Foundation Fellowship, 9/1/2020-8/31/2022, \$100,000 (\$50,000/year)

Collaborator, 3%, Targeting Anti-Apoptotic Pathways in MDS at that time of Progression, Evans MDS, PI - Colla, Simona, 9/1/2020-8/31/2023, \$545,454 (\$181,818/year)

Principal Investigator, 1.56 months, Mapping the Genetic and Phenotypic Heterogeneity in AML and Its Clinical Significance, FP00008946, American Society of Hematology (ASH), 7/1/2021-6/30/2023, \$150,000 (\$75,000/year)

Pending

Principal Investigator, 10%, Evolutionary Timing and Genetic Determinants of AML Transformation, FP00011843, Gabrielle's Angel Foundation for Cancer Research, 1/1/2021-12/31/2023, \$203,472 (\$67,824/year)

Other

Principal Investigator, 8%, Investigating intra-tumor heterogeneity and drug resistance in AML treated with IDH inhibitors, Withdrawn, FP00006905, Leukemia and Lymphoma Society, 7/1/2019-6/30/2022, \$535,934 (\$177,458/year)

Principal Investigator, 10%, Uncovering Clonal Diversity in Leukemia Stem Cells and its Potential as a Prognostic and Predictive Biomarker in AML, Withdrawn, FP00008716, Damon Runyon, 1/1/2020-12/31/2021, \$398,522 (\$199,261/year)

Completed

Principal Investigator, Clonal hematopoiesis in cancer patients predicts development of AML/MDS, 00, Red and Charline McCombs Institute Center for Global Cancer Early Detection at The University of Texas MD Anderson Cancer Center, 8/1/2015-7/31/2017, \$197,660 (\$197,660/year)

Co-Principal Investigator, 1%, Improving the recognition, treatment, and prevention strategies for patients with inherited predispositions to hematologic malignancies, P50 CA100632, UTMDACC Leukemia SPORE Career Enhancement Award, 9/1/2015-8/31/2017, \$96,328 (\$45,000/year)

Principal Investigator, UTMDACC Leukemia SPORE Career Development Award: Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS., P50CA100632, NIH/NCI, 9/1/2015-8/31/2017, \$18,545 (\$34,306/year)

Principal Investigator, 4.8 months, Clonal hematopoiesis in cancer patients predicts development of therapy-related AML/MDS, Institutional Research Grant at The University of Texas MD Anderson Cancer Center, 2/1/2016-1/31/2017, \$74,944 (\$74,944/year)

Principal Investigator, 1%, Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS, UTMDACC Leukemia SPORE Career Enhancement Program, 9/1/2016-8/31/2017, \$20,282 (\$20,282/year)

Principal Investigator, 20%, Early detection of therapy-related myeloid neoplasms using clonal hematopoiesis as a biomarker, Khalifa Scholar Award at The University of Texas MD Anderson Cancer Center, 10/1/2016-9/30/2018, \$300,000 (\$150,000/year)

Co-Investigator, 1%, Improving Prediction of Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Next-Generation Sequencing, FP00000098, Conquer Cancer Foundation, PI - Short N, 7/1/2017-6/30/2018, \$47,500 (\$47,500/year)

Principal Investigator, 5%, Development of Single-Cell MRD Assay, Agilent Technologies, 1/1/2019-12/31/2019, \$42,492 (\$42,492/year)

Principal Investigator, 6%, UTMDACC Leukemia SPORE Development Award: Optimization and advancement of molecular MRD detection in AML, P50 CA100632-17, NIH/NCI, 9/1/2019-8/31/2020, \$50,000 (\$50,000/year)

Not Funded

Principal Investigator, 5%, Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS, 1, Mike Hogg Fund, 1/1/2016-12/31/2016, \$20,000 (\$20,000/year)

Principal Investigator, 5%, Identifying biomarkers that predict developments of therapy-related AML/MDS, Sabin Fellows Award, 1/1/2016-12/31/2017, \$100,000 (\$50,000/year)

Principal Investigator, 5%, Ladies Leukemia League, 6/1/2016-5/31/2017, \$30,000 (\$30,000/year)

Principal Investigator, 15%, Targeting clonal hematopoiesis to prevent therapy related myeloid neoplasms, FP00001936, Leukemia Research Foundation, 7/1/2017-6/30/2018, \$100,000 (\$100,000/year)

Co-Investigator, 10%, Understanding the mechanism of clonal evolution of CHiP to t-MDS, EvansMDS Foundation, PI - Garcia-Manero, 9/1/2017-8/31/2019, \$356,713 (\$178,356/year)

Principal Investigator, 10%, Characterizing clonal architecture and heterogeneity of clonal hematopoiesis of indeterminate, Dresner Foundation, 10/1/2017-9/30/2019, \$249,541 (\$124,771/year)

Principal Investigator, 10%, Identifying patients at risk of developing therapy-related myeloid neoplasms, FP00001771, Leukemia and Lymphoma Society, 10/1/2017-9/30/2020, \$542,051 (\$180,018/year)

Principal Investigator, 10%, Characterizing clonal architecture and epigenetic remodeling of CHIP, Gilead Sciences Inc., 1/1/2018-12/31/2019, \$11,700 (\$58,500/year)

Principal Investigator, 20%, Characterizing clonal evolution and epigenomic reprogramming during IDH inhibitor therapy in acute myeloid leukemia (AML), RP180489, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2018-2/28/2021, \$1,091,691 (\$372,997/year)

Co-Investigator, 5%, Preventing therapy-related leukemia and myelodysplastic syndromes, FP00002896, NIH/NCI, PI - Garcia-Manero G, 4/1/2018-3/31/2020, \$275,000 (\$125,000/year)

Principal Investigator, Characterizing clonal heterogeneity and remodeling of AML with single cell DNA sequencing, FP5083, Leukemia Research Foundation, 7/1/2018-6/30/2019, \$99,909 (\$100,000/year)

Principal Investigator, 15%, Investigating the mechanism of resistance to IDH inhibitor in AML, Conquer Cancer Foundation, 7/1/2018-6/30/2021, \$187,399 (\$62,466/year)

Principal Investigator, 5%, Precision Characterization of Clonal Diversity in AML and Its Clinical Implications, Emerson Collective, 2/1/2020-1/31/2022, \$173,694 (\$86,847/year)

Principal Investigator, 10%, Title of Proposal / Grant Application Precision Characterization of Clonal Diversity in AML and its Clinical Implications, The Leukemia & Lymphoma Society, 7/1/2020-6/30/2023, \$585,040 (\$195,013/year)

Principal Investigator, 10%, Elucidating the role of immune microenvironment in the progression of clonal hematopoiesis, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2020-8/30/2021, \$124,988 (\$124,988/year)

Principal Investigator, 10%, Understanding the Genetic Predisposition and the Role of Chemo-radiation Exposures for Therapy-related Myeloma Neoplasms, V Foundation, 7/1/2021-6/30/2023, \$545,091 (\$181,697/year)

Principal Investigator, Elucidating the Clonal Origin and Evolutionary History of Clonal Hematopoiesis of Indeterminate Potential (CHIP), FP00008822, Dressner, \$236,574 (\$118,287/year)

Protocols

Funded

N/A

Unfunded

N/A

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Dutch Cancer Society, Dutch Cancer Society, Reviewer, 2018-present

2020 GCC Dunn Foundation Collaborative Research Award Review, Dunn Foundation, Reviewer, 2020

Internal Review Study Section (INTEREST)., MD Anderson Cancer Center, Reviewer, 2020-present

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. **Takahashi K**, Inuzuka M, Ingi T. Cellular signaling mediated by calphoglin-induced activation of IPP and PGM. *Biochem Biophys Res Commun* 325(1):203-14, 12/2004. PMID: 15522220.
2. Takagi S, Ota Y, Uchida N, **Takahashi K**, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. *Blood* 116(4):649-52, 7/2010. e-Pub 5/2010. PMID: 20439618.
3. Kato S, **Takahashi K**, Ayabe K, Samad R, Fukaya E, Friedmann P, Varma M, Bergmann SR. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. *Br J Haematol* 154(3):373-7, 8/2011. e-Pub 5/2011. PMID: 21615718.
4. Takahashi K, Yabe M, Shapira I, Pierce S, Garcia-Manero G, Varma M. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. *Leuk Res* 36(11):1376-9, 11/2012. e-Pub 8/2012. PMID: 22917767.
5. Tsai JJ, Dudakov JA, **Takahashi K**, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR. Nrf2 regulates haematopoietic stem cell function. *Nat Cell Biol* 15(3):309-16, 3/2013. e-Pub 2/2013. PMID: PMC3699879.
6. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. *Leuk Res* 37(5):552-5, 5/2013. e-Pub 2/2013. PMID: PMC4408989.
7. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. *Br J Haematol* 161(5):659-66, 6/2013. e-Pub 3/2013. PMID: PMC4068703.

8. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. *Am J Hematol* 88(10):831-7, 10/2013. e-Pub 7/2013. PMCID: PMC3923606.
9. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. *Blood* 122(16):2807-11; quiz 2920, 10/2013. e-Pub 7/2013. PMCID: PMC3798995.
10. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. *Leukemia* 27(10):2081-3, 10/2013. e-Pub 6/2013. PMID: 23774633.
11. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. *Nat Rev Genet* 14(10):703-18, 10/2013. e-Pub 9/2013. PMCID: PMC4014352.
12. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. *Blood* 122(23):3784-6, 11/2013. e-Pub 9/2013. PMCID: PMC3952679.
13. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 15(2):110-4, 2/2015. e-Pub 7/2014. PMCID: PMC4294996.
14. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. *Am J Hematol* 90(7):E134-5, <http://onlinelibrary.wiley.com/doi/10.1002/ajh.24009/abstract>, 7/2015. e-Pub 3/2015. PMCID: PMC4948743.
15. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. *Am J Hematol* 90(8):732-6, 8/2015. e-Pub 5/2015. PMCID: PMC4612499.
16. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. *Am J Hematol* 90(8):752-3, 8/2015. e-Pub 4/2015. PMCID: PMC4509849.
17. Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. *Am J Hematol* 90(11):E211-2, 11/2015. e-Pub 10/2015. PMCID: PMC4807602.
18. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemester FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. *Br J Haematol* 171(5):726-35, 12/2015. e-Pub 9/2015. PMCID: PMC4715651.
19. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannon Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leuk Res* 39(12):1367-74, 12/2015. e-Pub 10/2015. PMCID: PMC4822515.
20. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival

- in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. *Cancer* 122(2):238-48, 1/2016. e-Pub 10/2015. PMID: PMC4707980.
21. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. *Oncotarget* 7(12):14172-87, 3/2016. e-Pub 2/2016. PMID: PMC4924706.
 22. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients. *Clin Lymphoma Myeloma Leuk* 16(3):163-8.e1-2, 3/2016. e-Pub 11/2015. PMID: PMC4804759.
 23. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. *Oncotarget* 7(12):14251-8, 3/2016. e-Pub 2/2016. PMID: PMC4924712.
 24. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannon Z, Ganon-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boulwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. *Br J Haematol* 173(1):161-5, 4/2016. e-Pub 6/2015. PMID: PMC5580681.
 25. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. *Leukemia* 30(4):980-4, 4/2016. e-Pub 7/2015. PMID: PMC4733599.
 26. Cabrero M, Wei Y, Yang H, Ganon-Gomez I, Bohannon Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. *Leuk Res* 44:1-7, 5/2016. e-Pub 2/2016. PMID: PMC6186146.
 27. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. *Am J Hematol* 91(4):E274-6, 6/2016. e-Pub 2/2016. PMID: 26798971.
 28. DiNardo CD, Bannan SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). *Clin Lymphoma Myeloma Leuk* 16(7):417-428.e2, 7/2016. e-Pub 4/2016. PMID: PMC4925265.
 29. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. *Haematologica* 101(8):e324-7, 8/2016. e-Pub 5/2016. PMID: PMC4967581.
 30. Chamseddine AN, Cabrero M, Wei Y, Ganon-Gomez I, Colla S, Takahashi K, Yang H, Bohannon ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Clin Lymphoma Myeloma Leuk* 16 Suppl:S67-73, 8/2016. PMID: 27521329.
 31. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. *Clin Case Rep* 4(8):765-7, 8/2016. e-Pub 7/2016. PMID: PMC4974424.
 32. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with

- chronic myeloid leukemia in chronic phase. *Cancer* 122(21):3336-3343, 11/2016. e-Pub 8/2016. PMID: PMC5073019.
33. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. *Clin Lymphoma Myeloma Leuk* 16(11):616-624, 11/2016. e-Pub 8/2016. PMID: PMC5408349.
 34. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer* 122(22):3484-3491, 11/2016. e-Pub 7/2016. PMID: PMC5269552.
 35. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *Lancet Oncol* 18(1):100-111, 1/2017. e-Pub 12/2016. PMID: PMC5405697.
 36. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. *Nature* 542(7641):362-366, 2/2017. e-Pub 2/2017. PMID: PMC7609022.
 37. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. *Blood Adv* 1(15):1031-1036, <https://doi.org/10.1182/bloodadvances.2017007922>, 6/2017. e-Pub 6/2017. PMID: PMC5728325.
 38. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. *Am J Hematol* 92(7):599-606, 7/2017. e-Pub 5/2017. PMID: PMC5553721.
 39. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Adv* 1(17):1312-1323, 7/2017. e-Pub 7/2017. PMID: PMC5727976.
 40. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. *Cancer* 123(16):3050-3060, 8/2017. e-Pub 4/2017. PMID: PMC5544569.
 41. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Houry JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. *Cancer* 123(19):3717-3724, 10/2017. e-Pub 6/2017. PMID: PMC5689475.
 42. Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3-ITD status in newly diagnosed AML. *Leukemia* 31(11):2526-2529, 11/2017. e-Pub 7/2017. PMID: 28751773.
 43. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed

- Philadelphia Chromosome-positive Leukemia. *Clin Lymphoma Myeloma Leuk* 17(12):897-901, 12/2017. e-Pub 8/2017. PMID: 28927784.
44. Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. *Clin Cancer Res* 24(1):43-51, 1/2018. e-Pub 10/2017. PMID: 29030354.
 45. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Oncotarget* 9(11):9714-9727, 2/2018. e-Pub 1/2018. PMCID: PMC5839396.
 46. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. *JAMA Oncol* 4(2):230-234, 2/2018. e-Pub 8/2017. PMCID: PMC5838597.
 47. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. *Cancer* 124(6):1160-1168, 3/2018. e-Pub 12/2017. PMCID: PMC5851790.
 48. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood* 131(16):1820-1832, 4/2018. e-Pub 1/2018. PMCID: PMC5909764.
 49. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. *J Clin Oncol* 36(18):JCO2017776757, 6/2018. e-Pub 4/2018. PMCID: PMC6008108.
 50. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer* 124(13):2740-2747, 7/2018. e-Pub 5/2018. PMCID: PMC6388399.
 51. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. *Cancer* 124(13):2704-2713, 7/2018. e-Pub 4/2018. PMID: 29682723.
 52. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. *Nat Commun* 9(1):2670, 7/2018. e-Pub 7/2018. PMCID: PMC6039465.
 53. Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, Chen TX, Geis JA, Oldham W, Matthews J, Kantarjian H, Futreal PA, Patel K, Jones KW, Takahashi K, Eastburn DJ. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors

- with droplet microfluidics. *Genome Res* 28(9):1345-1352, 9/2018. e-Pub 8/2018. PMID: PMC6120635.
54. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. *Leuk Lymphoma* 59(9):1-4, 9/2018. e-Pub 1/2018. PMID: 29338567.
 55. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. *Blood* 132(16):1664-1674, 10/2018. e-Pub 9/2018. PMID: PMC6265645.
 56. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, Vassiliou G, Futreal PA, Donehower LA, Takahashi K, Goodell MA. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. *Cell Stem Cell* 23(5):700-713.e6, 11/2018. PMID: PMC6224657.
 57. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. *Am J Hematol* 94(1):74-79, 1/2019. e-Pub 11/2018. PMID: PMC6570401.
 58. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? *Blood Cancer J* 9(2):7, 1/2019. e-Pub 1/2019. PMID: PMC6335405.
 59. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leuk Lymphoma* 60(1):1-12, 1/2019. e-Pub 5/2018. PMID: PMC6226369.
 60. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. *Cold Spring Harb Mol Case Stud* 5(1), 2/2019. e-Pub 2/2019. PMID: PMC6371746.
 61. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. *Blood Adv* 3(4):508-518, 2/2019. PMID: PMC6391673.
 62. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv* 3(6):922-933, 3/2019. PMID: PMC6436014.
 63. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 19(3):142-148.e1, 3/2019. e-Pub 12/2018. PMID: 30635233.

64. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. *Blood Adv* 3(9):1533-1539, 5/2019. PMID: PMC6517659.
65. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. *N Engl J Med* 380(22):2095-2103, 5/2019. PMID: 31141631.
66. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Int J Hematol* 109(5):545-552, 5/2019. e-Pub 3/2019. PMID: 30830579.
67. Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. *Oncologist* 24(6):772-782, 6/2019. e-Pub 11/2018. PMID: PMC6656515.
68. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. *Am J Hematol* 94(6):E158-E160, 6/2019. e-Pub 3/2019. PMID: PMC6602057.
69. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Noguera Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. *Cancer* 125(13):2233-2241, 7/2019. e-Pub 3/2019. PMID: PMC6742577.
70. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Houry JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. *Blood* 134(1):59-73, 7/2019. e-Pub 4/2019. PMID: PMC6609954.
71. Hu T, Morita K, Hill MC, Jiang Y, Kitano A, Saito Y, Wang F, Mao X, Hoegenauer KA, Morishita K, Martin JF, Futreal PA, Takahashi K, Nakada D. PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells. *Blood* 134(7):614-625, 8/2019. e-Pub 7/2019. PMID: PMC6695560.
72. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. *Lancet Haematol* 6(9):e480-e488, 9/2019. e-Pub 8/2019. PMID: PMC6778960.
73. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. *Br J Haematol* 187(1):e1-e4, 10/2019. e-Pub 7/2019. PMID: 31344256.
74. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer* 126(1):67-75, 1/2020. e-Pub 9/2019. PMID: 31553487.

75. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. *Blood Adv* 4(3):482-495, 2/2020. PMID: PMC7013259.
76. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. *Cancer* 126(4):765-774, 2/2020. e-Pub 11/2019. PMID: 31742675.
77. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. *Am J Hematol* 95(2):144-150, 2/2020. e-Pub 11/2019. PMID: 31682008.
78. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. *Clin Infect Dis*. e-Pub 4/2020. PMID: 32236406.
79. Saenz DT, Fiskus W, Mill CP, Perera D, Manshoury T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β -catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. *Blood* 135(15):1255-1269, 4/2020. e-Pub 2/2020. PMID: PMC7146021.
80. Lachowiec CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. *Blood Adv* 4(7):1311-1320, 4/2020. PMID: PMC7160266.
81. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. *Blood Adv* 4(8):1670-1677, 4/2020. PMID: PMC7189293.
82. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. *Am J Hematol* 95(6):612-622, 6/2020. e-Pub 3/2020. PMID: 32112433.
83. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematol* 7(7):e523-e533, 7/2020. PMID: 32589978.
84. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannan SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-

- Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. *Epigenetics*:1-10. e-Pub 8/2020. PMID: 32856987.
85. Aitken MJL, Benton CB, Wang F, Zhang J, Herbrich SM, Takahashi K, Bueso-Ramos CE, Short NJ. 33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient. *Am J Hematol* 95(9):1117-1120, 9/2020. e-Pub 5/2020. PMID: 32356323.
 86. Wang W, Beird H, Kroll CJ, Hu S, Bueso-Ramos CE, Fang H, Tang G, Tang Z, Wang F, Takahashi K, You MJ, Khoury JD, Medeiros LJ, Futreal PA. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. *Leukemia* 34(9):2509-2512, 9/2020. e-Pub 2/2020. PMID: 32099038.
 87. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol* 7(10):e724-e736, 10/2020. e-Pub 9/2020. PMCID: PMC7549397.
 88. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat Commun* 11(1):5327, 10/2020. e-Pub 10/2020. PMCID: PMC7577981.
 89. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 13(1):132, 10/2020. e-Pub 10/2020. PMCID: PMC7542942.
 90. Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nat Genet* 52(11):1219-1226, 11/2020. e-Pub 10/2020. PMCID: PMC7891089.
 91. Lachowiec C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. *Am J Hematol* 95(11):E313-E315, 11/2020. e-Pub 9/2020. PMID: 32804409.
 92. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia* 34(11):2914-2924, 11/2020. e-Pub 6/2020. PMID: 32546726.
 93. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv* 4(22):5681-5689, 11/2020. PMCID: PMC7686900.

94. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat Commun* 11(1):5996, 11/2020. e-Pub 11/2020. PMID: PMC7677309.
95. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). *Am J Hematol* 95(12):E326-E329, 12/2020. e-Pub 10/2020. PMID: 32886803.
96. Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. *Front Oncol* 10:1538, 2020. e-Pub 8/2020. PMID: PMC7479234.
97. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Front Oncol* 10:582213, 2020. e-Pub 1/2021. PMID: PMC7878971.
98. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. *Cancer* 127(3):381-390, 2/2021. e-Pub 10/2020. PMID: 33119202.
99. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. *Am J Hematol* 96(2):E50-E53, 2/2021. e-Pub 11/2020. PMID: 33156969.
100. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol* 14(1):34, 2/2021. e-Pub 2/2021. PMID: 33618754.
101. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. *Am J Hematol*. e-Pub 2/2021. PMID: 33580980.
102. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. *Br J Haematol*. e-Pub 2/2021. PMID: 33618432.
103. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. *Am J Hematol*. e-Pub 2/2021. PMID: 33639000.

104. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. *Am J Hematol* 96(2):241-250, 2/2021. e-Pub 12/2020. PMID: 33180322.
105. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J* 11(2):25, 2/2021. e-Pub 2/2021. PMID: PMC7873265.
106. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica* 106(3):894-898, 3/2021. e-Pub 3/2021. PMID: 32499238.
107. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. *Am J Hematol* 96(3):282-291, 3/2021. e-Pub 12/2020. PMID: 33264443.

Invited Articles

1. Takahashi K. Germline polymorphisms and the risk of therapy-related myeloid neoplasms. *Best Pract Res Clin Haematol* 32(1):24-30, 3/2019. e-Pub 2/2019. PMID: 30927971.

Editorials

1. Takahashi K. Ups and downs of CHIP. *Blood* 131(16):1773-1774, 4/2018. PMID: 29674353.
2. Takahashi K. AML: Predicting the Unpredictable. *Cell Stem Cell* 23(2):162-163, 8/2018. PMID: 30075128.
3. Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. *J Clin Oncol* 37(1):7-11, 1/2019. e-Pub 11/2018. PMID: PMC6354773.

Other Articles

N/A

Abstracts

N/A

Book Chapters

N/A

Books (edited and written)

N/A

Letters to the Editor

1. Montalban-Bravo , Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. *N Engl J Med* 376(8):796-7, 2/2017. PMID: 28229579.
2. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood* 129(18):2584-2587, 5/2017. e-Pub 2/2017. PMID: PMC5418636.

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Review Editor, Frontiers in Immunology, 2016-present

Member of Editorial Review Board

Editorial Advisory Board, The Pharmaceutical Journal, 2016-present

Journal Reviewer

Reviewer, Clinical Lymphoma Myeloma and Leukemia, Elsevier, 2015-present

Reviewer, Leukemia, Nature Publishing Group, 2015-present

Reviewer, Blood, 2016-present

Reviewer, JAMA Oncology, 2016-present

Reviewer, Oncotarget, 2016-present

Reviewer, American Journal of Human Genetics, 2017-present

Reviewer, Scientific Reports, 2017-present

Reviewer, Blood Advances, 2018-present

Reviewer, Cancer Research, 2018-present

Reviewer, Haematologica, 2018-present

Reviewer, Leukemia Research, 2018-present

Reviewer, Nature Communications, 2018-present

Reviewer, Nature, 2019-present

Reviewer, Nucleic Acid Research, 2019-present

Reviewer, Leukemia and Lymphoma, 2020-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

Research Advisor, Research Advisory Committee, Hematology Oncology Fellowship Program, Boyu Hu, MD, 1/2017-present

Committee Member, MS Advisory Committee, Graduate School of Biomedical Sciences, Shuaitong Chen, MS, 8/2019

Committee Member, Master Degree Committee, Master for Science, Vivian Salama, MSc

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

Research Mentor, Graduate School, Kiyomi Morita MD, PhD, 4/2017-present

Raghav Ramabadran, 8/2020-12/2020

Postdoctoral Research Fellows

Research Mentor, Ken Furudate, DDS PhD, 4/2019

Research Mentor, Tomoyyuki Tanaka, MD, PhD, 4/2019

Research Mentor, Yuya Sasaki MD, PhD, 6/2019

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

Research Mentor, Feng Wang PhD, 1/2015

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Lecturer, Leukemia Master Class, BioMedical Learning Institute

10/2018

Supervisory Teaching

Committees

Advisory Committees

Committee Member, Baylor College of Medicine, Kapadia Chiraag Deepak, PhD,

8/2019

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

Research Mentor, Rice University, Yi June Kim, 4/2019

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Japanese Society of Hematology, Tokyo, Japan, Chair, 10/2019

Presentations at National or International Conferences

Invited

Takahashi K.. Next Steps with CHIP and Myeloid Neoplasms-Informing Risk and Prevention, 59th American Society of Hematology Annual Meeting, American Society of Hematology, Atlanta, GA, 12/8/2017

Takahashi K. Leukemic Potential of clonal hematopoiesis and the association with external stressors, Clonal Hematopoiesis Workshop, Radiation Effects Research Foundation, Hiroshima, Japan, 1/10/2019

Takahashi K. Single-cell atlas of driver mutations in AML, Single cell Biology Meets Diagnostics, Uppsala University, Uppsala, Sweden, 3/4/2019

Takahashi K. Clonal heterogeneity in AML, 6th Annual Global Summit on Hematologic Malignancies, DAVA Oncology, Whistler, Canada, 3/15/2019

Takahashi. Unraveling clonal heterogeneity and evolutionary history of AML by single-cell NDA sequencing, AACR Annual Meeting, AACR, Atlanta, GA, 4/1/2019

Takahashi K. Delineating clonal diversity of AML by single-cell genomics, Leukemia SPORE Career Enhancement Program, University of Washington at St. Louis, St. Louis, MO, 9/18/2019

Takahashi. Clonal heterogeneity of AML and its clinical implications, Single Cell Symposium, University of Helsinki, Helsinki, Finland, 9/23/2019

Takahashi. Single-cell DNA sequencing delineates clonal diversity of AML, ETH Zurich Basel, Basel, 9/24/2019

Takahashi K. Precision clonal mapping in acute myeloid leukemia with single-cell genomics, D5 Medical & Life Science Seminar, International Research Center for Medical Sciences (IRCMS)., Virtual, 7/8/2020

Takahashi K. The Spectrum of Clonal Hematopoiesis from CHIP to AML, SOHO 2020, Society of Hematologic Oncology, Houston, TX, 9/9/2020

Takahashi K. Clonal heterogeneity and evolution of acute myeloid leukemia, AACR Virtual Special Conference: Tumor Heterogeneity: From Single Cells to Clinical Impact, American Association for Cancer Research, 9/17/2020

takahashi K. Single Cell Insights into Myeloid Neoplasia, AMP 2020 Annual Meeting & Expo: Virtual Education & Networking Experience, Association for Molecular Pathology, Virtual, 11/17/2020

Other, Including Scientific Exhibitions

Takahashi, K. Distinct clinical feature Myelodysplastic syndrom in Human Immunodeficiency Virus (HIV) infected patients, 53rd Annual Meeting of American Society of Hematology, American Society of Hematology, San Diego, CA, 2011

Takahashi K.. FLT3 inhibitors are promising salvage therapy for relapsed or refractory Acute Myeloid Leukemia (AML) in patients with FLT3-ITD mutations, 53rd Annual Meeting of American Society of Hematology, American Society of Hematology, San Diego, CA, 2011

Takahashi K.. Cytogenetic Characteristics of Myelodysplastic Syndrom in Human Immunodeficiency Virus Infected Patients: High Incidence of Poor Prognostic Karyotype and Chromosome 7 Abnormalities, 16th Congress of Eurpoean Hematology Association, European Hematology Association, London, London, United Kingdom, 6/2011

Takahashi K. Kantarjian H. Abruzzo L. Borthakur G, Garcia-Manero G. O'Brien S, Faderl S, Luthra R, Wierda W, Ferrajoli A, Pierce S, Ravandi F, Cortes J.. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis, 54th Annual Meeting of American Society of Hematology, American Society of Hematology, Atlanta, GA, 2012

Takahashi K.. Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure, 54th Annual Meeing of American Society of Hematology, American Society of Hematology, Atlanta, GA, 2012

Takahashi K.. Refined MDA Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML), 54th Annual Meeting of American Society of Hematology, American Society of Hematology, Atlanta, GA, 2012

Takahashi K.. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma, 54th Annual Meeting of American Society of Hematology, American Society of Hematology, Atlanta, GA, 2012

Takahashi K.. Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis, 54th Annual Meeting of American Society of Hematology, American Society of Hematology, Atlanta, GA, 2012

Takahashi K.. A Phase II Expansion Study of Vorinostate in combination with Idarubicin and Cytarabin for Patients with Acute Myelogenous Leukemia (AML) with FLT3 Molecular Alterations, 55th Annual Meeting of American Society of Hematology, American Society of Hematology, New Orleans, LA, 2013

Takahashi K, Garcia-Manero G, Cortes J, Ravandi F, Faderl S, O'Brien S, Kantarjian H, Borthakur G. Fludarabine and cytarabine based induction therapy is associated with high response rate and durable remission with low treatment related mortality in elderly patients with core-binding factor (AML (CBF-AML), 55th Annual Meeting of American Society of Hematology, American Society of Hematology, New Orleans, LA, 2013

Takahasi, K.. MD Anderson's Oncology Expert Advisor™ powered by IBM Watson, a web based cognitive clinical decision support tool, 50th Annual Meeting of American Society of Clinical Oncology, ASCO, Chicago, IL, 2014

Takahashi K, Jain P, Jabbour E, Wierda W, Pemmaraju N, Ferrajoli A, Dellasala S, Pierce S, Verstovsek S, Ranvandi F, O'Brien E, Cortes J. Propensity score matched comparison of dasatinib and nilotinib as a frontline therapy in newly diagnosed CML with chronic phase, 16th Annual John Goldman Conference, iCMLF, Phliadelphia, PA, 2014

Takahashi K.. Propensity score matched comparison of intermediate-intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age >60) with acute myeloid leukemia (AML), 19th Congress of European Haematology Associaiton, European Hematology Association, Milan, Italy, 2014

[b Takahashi K], Wang F, Kantarjian H, Denaha D, Khanna K, Thompson E, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo C, Colla S, Ravandi F, Song X, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A. Clonal origin of therapy related myeloid neoplasms, 21st Congress of European Haematology Associaiton, European Hematology Association, Copenhagen, Denmark, 6/11/2016

Takahashi K , Wang F, Kantarjian H, Denaha D, Khanna K, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo C, Colla S, Ravandi F, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A.. Clonal hematopoiesis increases risk of therapy-related myeloid

neoplasms, 58th American Society of Hematology Annual Meeting, American Society of Hematology, San Diego, CA, 12/3/2016

Takahashi K, Wang F, Patel K, Bueso-Ramos C, Issa G, Song X, Zhang J, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes J, Garcia-Manero G, Jabbour E, Futreal A, Kantarjian H. Persistence of preleukemic clonal hematopoiesis after chemotherapy is associated with poor prognosis in patients with high risk MDS and AML, The 14th International Symposium on Myelodysplastic Syndrome, MDS Foundation, Valencia, Spain, 5/4/2017

Takahashi K, Wang F, Patel K, Bueso-Ramos C, Issa G, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes J, Garcia-Manero G, Jabbour E, Futreal P, Kantarjian H. Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML, ASCO Annual Meeting, ASCO, Chicago, IL, 6/2017

Seminar Invitations from Other Institutions

Comparative analysis of residency training between Japan and United States, Residency Seminar, Toranomon Hospital, Japan, 2010

Oncology Practice in United States, 1st Senshu Oncology Seminar, Izumi General Hospital, Japan, 2013

Residency training and beyond, Niigata University of School of Medicine, Project Grant for Promotion of Global Human Resources, Japan, 2014

Residency training and clinical research in United States, Dept. of Endocrinology and Hematology, Niigata University, Japan, 2014

Molecular diagnosis of MDS, MDS Foundation, Houston, TX, 11/9/2015

Molecular diagnosis of MDS, MDS Foundation, Houston, TX, 5/23/2016

Clinical implications of clonal hematopoiesis, Juntendo University, Japan, 7/2016

Clinical residency training abroad, Niigata University, Japan, 7/2016

Molecular diagnosis of MDS, MDS Foundation, Houston, TX, 6/12/2017

Genomic landscape of mixed phenotype acute leukemia, Global Academic Program, Tokyo Oncology Consortium, Tokyo, Japan, 9/29/2017

Genomic landscape of acute mixed phenotype leukemia, Kyowa Hakko Kirin Co. Ltd., 6th Cancer Stem Cell Symposium, Fukuoka, Fukuoka, Japan, 11/11/2017

Evolution of AML genome and epigenome during therapy, Kumamoto University International Research Center for Medical Science, Kumamoto, Japan, 4/23/2018

Clinical implications of clonal hematopoiesis, Radiation Effect Research Foundation, Hiroshima, Japan, 1/10/2019

Clinical implications of clonal hematopoiesis, Hiroshima University, Department of Hematology, Hiroshima, Japan, 1/11/2019

Single-cell atlas of acute myeloid leukemia, Uppsala University, Uppsala, Sweden, 3/4/2019

Lectureships and Visiting Professorships

Visiting Assistant Professor, Kumamoto University, The International Research Center for Medical Sciences, Kumamoto, Kumamoto, Japan, 5/1/2017

Other Presentations at State and Local Conferences

IgA nephropathy with a clinical course of progressive renal failure, Japanese Society of Nephrology Eastern Japan Conference, Japanese Society of Nephrology, 2007

Granulomatosis Arteritis presented with Eosinophilic Myositis, Kanto Conference, Japanese Society of Neurology, Japan, 2008

Distinct Clinical Characteristic of Myelodysplastic Syndrome in Human Immunodeficiency Virus Infected Patients, 9th Annual Research Fair at Beth Israel Medical Center, Beth Israel Hospital, New York, NY, 2011

Takahashi K. Think Tank for clonal hematopoiesis, Leukemia Planning Clinic, MD Anderson Cancer Center, Leukemia, Houston, TX, 2/14/2019

Takahashi K. Think Tank for Clonal Hematopoiesis, Leukemia Planning Meeting, MD Anderson Cancer Center, Leukemia, Houston, TX, 3/7/2019

Takahashi K. Clinical and intratumor heterogeneity of leukemia, Leukemia Research Meeting, MD Anderson Cancer Center, Leukemia, Houston, TX, 3/27/2019

Takahashi K. Genomics and environmental contribution for therapy-related myeloid neoplasms, Emil J Freireich Hematology Grand Rounds, MD Anderson Cancer Center, Department of Leukemia, Houston, TX, 10/30/2019

Takahashi K. Can Unravelling Clonal Evolution in AML Help Guide Therapy with Today's Drugs?, Expert Forum on Acute Leukemias, DAVA Oncology, Dallas, TX, 2/28/2020

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

Japanese Society of Hematology, Japan
Member, 2008-present

American College of Physicians
Member, 1/2011-present

American Society of Clinical Oncology
Member, 1/2011-present

American Society of Hematology
Member, 1/2011-present

Society of Hematology Oncology (SOHO), Houston, TX
Member, 10/2012-present

American Association of Cancer Research
Member, 1/2014-present

European Haematology Association
Junior Member, 1/2014-present

Local/State

N/A

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

3/2/2021